Regeneron Pharmaceuticals, Inc. (REGN)
828.72
-5.32
(-0.64%)
USD |
NASDAQ |
Aug 24, 16:00
834.55
+5.83
(+0.70%)
After-Hours: 20:00
Regeneron Pharmaceuticals Market Cap : 85.69B for Aug. 24, 2026
Market Cap Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Market Cap Data
| Date | Value |
|---|---|
| August 21, 2026 | 86.24B |
| August 20, 2026 | 85.47B |
| August 19, 2026 | 86.94B |
| August 18, 2026 | 83.78B |
| August 17, 2026 | 83.33B |
| August 14, 2026 | 83.08B |
| August 13, 2026 | 83.34B |
| August 12, 2026 | 82.51B |
| August 11, 2026 | 82.41B |
| August 10, 2026 | 83.55B |
| August 07, 2026 | 81.10B |
| August 06, 2026 | 79.84B |
| August 05, 2026 | 79.47B |
| August 04, 2026 | 78.65B |
| August 03, 2026 | 78.51B |
| July 31, 2026 | 78.86B |
| July 30, 2026 | 76.34B |
| July 29, 2026 | 71.91B |
| July 28, 2026 | 71.88B |
| July 27, 2026 | 68.99B |
| July 24, 2026 | 67.83B |
| July 23, 2026 | 67.41B |
| July 22, 2026 | 67.33B |
| July 21, 2026 | 69.81B |
| July 20, 2026 | 69.50B |
| Date | Value |
|---|---|
| July 17, 2026 | 69.97B |
| July 16, 2026 | 70.20B |
| July 15, 2026 | 68.70B |
| July 14, 2026 | 67.84B |
| July 13, 2026 | 68.56B |
| July 10, 2026 | 68.71B |
| July 09, 2026 | 69.07B |
| July 08, 2026 | 68.54B |
| July 07, 2026 | 69.92B |
| July 06, 2026 | 67.19B |
| July 02, 2026 | 67.65B |
| July 01, 2026 | 64.60B |
| June 30, 2026 | 64.47B |
| June 29, 2026 | 66.34B |
| June 26, 2026 | 66.45B |
| June 25, 2026 | 65.11B |
| June 24, 2026 | 65.46B |
| June 23, 2026 | 64.89B |
| June 22, 2026 | 64.31B |
| June 18, 2026 | 64.04B |
| June 17, 2026 | 63.83B |
| June 16, 2026 | 64.55B |
| June 15, 2026 | 64.57B |
| June 12, 2026 | 64.27B |
| June 11, 2026 | 64.21B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Alnylam Pharmaceuticals, Inc. | 31.57B |
| Gilead Sciences, Inc. | 182.13B |
| AbbVie, Inc. | 467.37B |
| Vertex Pharmaceuticals, Inc. | 138.77B |
| Amgen, Inc. | 239.94B |
Market Cap Related Metrics
| PE Ratio | 20.48 |
| PS Ratio | 5.713 |
| PEG Ratio | 10.48 |
| Price to Book Value | 2.702 |
| Price to Free Cash Flow | 24.83 |
| Price | 828.72 |
| Earnings Yield | 4.88% |
| PEGY Ratio | 8.543 |
| Operating PE Ratio | 21.26 |
| Normalized PE Ratio | 19.32 |